Audentes Therapeutics (NASDAQ:BOLD) had its price target boosted by Svb Leerink from $37.00 to $48.00 in a report released on Wednesday, BenzingaRatingsTable reports. The firm currently has an outperform rating on the biotechnology company’s stock.
Several other analysts have also issued reports on the company. ValuEngine lowered Audentes Therapeutics from a strong-buy rating to a buy rating in a research note on Monday, April 15th. Wedbush upped their target price on Audentes Therapeutics from $52.00 to $57.00 and gave the stock an outperform rating in a research note on Tuesday, April 9th. Piper Jaffray Companies upped their target price on Audentes Therapeutics from $45.00 to $55.00 and gave the stock a positive rating in a research note on Monday, April 8th. HC Wainwright reaffirmed a buy rating and issued a $44.00 target price (up previously from $33.00) on shares of Audentes Therapeutics in a research note on Monday, March 18th. Finally, Zacks Investment Research lowered Audentes Therapeutics from a buy rating to a hold rating in a research note on Tuesday, March 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $38.76.
BOLD stock opened at $38.90 on Wednesday. The company has a market capitalization of $1.66 billion, a P/E ratio of -11.44 and a beta of 1.96. Audentes Therapeutics has a 1-year low of $17.95 and a 1-year high of $46.18.
Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.08. During the same quarter in the prior year, the firm earned ($0.82) earnings per share. On average, analysts anticipate that Audentes Therapeutics will post -3.83 EPS for the current year.
In other news, VP Suyash Prasad sold 10,000 shares of the stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $30.06, for a total transaction of $300,600.00. Following the completion of the sale, the vice president now owns 28,236 shares of the company’s stock, valued at $848,774.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Matthew R. Patterson sold 21,000 shares of the stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $30.00, for a total value of $630,000.00. Following the sale, the chief executive officer now directly owns 135,700 shares of the company’s stock, valued at approximately $4,071,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,000 shares of company stock valued at $1,650,600. 6.60% of the stock is owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Partner Fund Management L.P. boosted its stake in shares of Audentes Therapeutics by 94.4% during the fourth quarter. Partner Fund Management L.P. now owns 3,021,259 shares of the biotechnology company’s stock valued at $64,413,000 after purchasing an additional 1,467,120 shares during the period. BlackRock Inc. boosted its stake in shares of Audentes Therapeutics by 15.8% during the fourth quarter. BlackRock Inc. now owns 2,974,591 shares of the biotechnology company’s stock valued at $63,418,000 after purchasing an additional 406,605 shares during the period. Great Point Partners LLC purchased a new stake in shares of Audentes Therapeutics during the fourth quarter valued at approximately $35,346,000. Vanguard Group Inc boosted its stake in shares of Audentes Therapeutics by 1.9% during the third quarter. Vanguard Group Inc now owns 1,342,931 shares of the biotechnology company’s stock valued at $53,166,000 after purchasing an additional 24,585 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Audentes Therapeutics by 1.9% during the third quarter. Vanguard Group Inc. now owns 1,342,931 shares of the biotechnology company’s stock valued at $53,166,000 after purchasing an additional 24,585 shares during the period.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: Bear Market – How and Why They Occur
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.